Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker GALT. The company focuses on drug research and development aimed at new treatments for fibrotic diseases, cancer, and other conditions. Its lead candidate is belapectin (GR-MD-02), a galectin-3 inhibitor being studied in a Phase 2b/3 trial to help prevent esophageal varices in patients with non-alcoholic steatohepatitis cirrhosis. Belapectin is also being evaluated in Phase 2 studies for liver fibrosis, severe skin disease, melanoma, and head and neck squamous cell carcinoma. The company also has a collaborative joint venture with SBH Sciences, Inc. through Galectin Sciences, LLC, focused on developing oral small-molecule galectin-3 inhibitors. Founded in 2000 and based in Norcross, Georgia, the company was previously known as Pro-Pharmaceuticals, Inc. before adopting its current name in 2011.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GALT
|
$2.90
|
-27.8% Downside
|
Overvalued
|
$11
|
174.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-10.0x
|
-2.0x
|
—
|
263.4 M
|
390.9 M
|
34.3%
|
71.7%
|
-40.6
|
—
|
75.9%
|
